Announcements Trials

Browse Landscape

Phase

Phase 3 1 Phase 2 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Prostatic Neoplasms 6 Breast Neoplasms 2 Small Cell Lung Carcinoma 1 Recurrence 1 Prostate Cancer Metastatic 1 Neoplasm Metastasis 1 Metastatic Breast Cancer With Intracranial Metastases 1 Lung Neoplasms 1 Hormone-Resistant Prostate Cancer 1 Diarrhea 1 Castrate-resistant Metastatic Prostate Cancer 1 Carcinoma, Transitional Cell 1 Brain Neoplasms 1

Interventions

enzalutamide 4 cabazitaxel 3 Docetaxel 3 Prednisone 2 talazoparib 1 rucaparib 1 pembrolizumab 1 olaparib 1 Zuclomiphene 1 XRP6258 1 Standard of Care 1 Radiosurgery 1 Positron Emission Tomography Computed Tomography 1 LY3023414 1 Injections 1 Carboplatin 1 Abituzumab 1 Abiraterone Acetate 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2 × Prostate Cancer Metastatic × XRP6258 × Clear all

NCT01718353 2017-11-20

TAXYNERGY

Sanofi

Phase 2 Completed

63 enrolled 13 charts

Prostate Cancer Metastatic

Data powered by HemOnc (CC BY 4.0) Colophon ⚡